Read articles from North America

October 06, 2026 by westernstandard.news

Canada’s nicotine policy has created a strange kind of protectionism: not for innovation, but for cigarettes. Smoke-free alternatives face restrictions, limited access and public confusion, while the product responsible for the greatest harm remains familiar and widely available. That imbalance matters because smokers respond to what is easiest, cheapest and most clearly explained. A policy that makes safer nicotine harder to reach is not neutral — it leaves cigarettes in the strongest position.

October 06, 2026 by protectingtaxpayers.org

The Fifth Circuit ruled that the FDA unlawfully imposed a comparative efficacy standard on flavored vaping products without the notice-and-comment process required by the Administrative Procedure Act. The standard required manufacturers to demonstrate greater benefits for adult smokers than tobacco-flavored products, contributing to widespread marketing denials. The text argues that these barriers restrict potentially lower-risk alternatives for smokers and increase healthcare costs. It also distinguishes lack of FDA authorization from proof that a product is dangerous, noting that authorization does not establish safety. The ruling calls for lawful, transparent regulation that protects young people, allows businesses fair participation, and preserves adult access to potentially beneficial alternatives to cigarettes.

October 05, 2026 by substack.com

The author argues that tobacco harm reduction (THR) should extend beyond helping current smokers switch to lower-risk nicotine products. US data show stable overall nicotine use alongside declining smoking and rising vaping, particularly among young adults. The author interprets these trends as suggesting that vaping may divert some people from smoking, although population trends alone cannot establish causation. THR could therefore include switching, maintaining smoking abstinence, and preventing smoking among would-be smokers. Whether vaping benefits never-smokers depends on whether they would otherwise smoke or remain nicotine-free. The author recommends broader messaging, research, and population models examining these counterfactuals to sustain THR’s relevance as cigarette smoking declines.

October 05, 2026 by junonews.com

Ian Irvine argues that Canada’s restrictions on nicotine pouches undermine smoking cessation by making lower-risk alternatives harder to buy than cigarettes. He criticizes the Ontario Tobacco Research Unit’s opposition to nicotine substitution, advocating harm reduction rather than eliminating all nicotine use. Citing vaping initiatives in New Zealand and the UK, alongside declining smoking rates in Sweden and Norway, he urges Ottawa to improve access to pouches, vapes and heated tobacco products. Although nicotine causes dependence, Irvine maintains that these alternatives pose substantially lower health risks than smoking. The article discloses that some of his research received tobacco-policy foundation funding and that nicotine producers covered conference expenses.

October 02, 2026 by reason.com

Easthampton became Massachusetts’ 25th municipality to adopt a lifetime nicotine-sales ban for younger generations, including noncombustible products. The author argues these policies conflate nicotine with smoking’s combustion-related harms and undermine harm reduction. Nicotine is addictive and carries cardiovascular and adolescent risks, but research suggests potential cognitive benefits, though therapeutic evidence remains preliminary. Comparing nicotine with caffeine and accepted nicotine-replacement therapies, the text criticizes restrictions on adult choice and the goal of eliminating nicotine use rather than smoking-related disease. It also warns that prohibition could encourage poorly studied, potentially stronger synthetic alternatives. The author advocates distinguishing nicotine from cigarettes and weighing its risks and benefits rather than treating it as inherently unacceptable.

October 02, 2026 by cspdailynews.com

The article portrays FDA tobacco director Bret Koplow as shifting regulation toward harm reduction after years of approval backlogs and limited support for cigarette alternatives. Speaking at a tobacco retailers’ conference, Koplow advocated cooperation with manufacturers and retailers to protect minors, accelerate authorization of scientifically supported lower-risk products for adults, and combat illicit e-cigarettes. His authorization of vaping and nicotine pouch products has drawn praise from industry and opposition from public health groups. Koplow emphasizes that no tobacco product is safe and quitting is healthiest, but completely switching from cigarettes to FDA-authorized, noncombustible alternatives can reduce exposure to toxic and cancer-causing chemicals.

October 02, 2026 by protectingtaxpayers.org

The text argues that growing evidence supports tobacco harm reduction products, especially e-cigarettes, as alternatives for adult smokers. It cites a Cochrane review of nine trials finding vaping more effective than traditional nicotine replacement therapies for quitting, with no serious harms identified in those trials. It also describes FDA authorization of reduced-risk marketing claims for ZYN nicotine pouches. The author contends that restrictive policies discourage cessation and fuel illicit markets, while cigarette smoking causes substantial mortality and economic costs. The text urges clinicians and policymakers to prioritize scientific evidence over stigma and prohibition, arguing that access to lower-risk nicotine products could improve public health.

October 01, 2026 by reason.com

Regulatory complexity has become part of the nicotine problem. A system too slow or difficult to navigate can leave legal smoke-free products waiting while cigarettes remain on shelves and unapproved alternatives fill the gaps. Streamlining FDA approvals would not mean lowering the evidentiary bar; it would mean making science-based decisions in time to matter. Harm reduction needs a pathway that is rigorous, workable and capable of bringing responsible products into the legal market.

September 30, 2026 by clearingtheair.eu

A claim from the top of government can shape what thousands of smokers believe about risk. Describing vaping and cigarettes in a way that blurs their differences does not protect public health; it can make lower-risk choices look pointless. Researchers challenging the Irish PM’s statement should be taken seriously because risk communication has consequences. Political messages on nicotine need to be accurate, proportionate and clear about the far greater harms of combustion.

September 30, 2026 by clivebates.com

A signature can turn uncertainty into authority. That is why public health statements on nicotine deserve careful reading before names are added to them. Claims about vaping, pouches or other smoke-free products can influence policy, clinical advice and the choices smokers believe are available. Experts should sign only what reflects the evidence clearly — including the difference between nicotine use and the far greater harms of combustion.